Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma

作者：Chen Chi Chang^*; Hess Gregory P; Liu Zhimei; Gesme Dean H; Agarwala Sanjiv S; Garay Carlos C; Hill Jerrold W; Guo Amy

来源：Clinical Genitourinary Cancer, 2012, 10(4): 256-261.

DOI：10.1016/j.clgc.2012.04.006

• Everolimus
• Metastatic renal cell carcinoma
• Sorafenib
• Temsirolimus
• Tyrosine kinase inhibitor

This study evaluated the treatment outcomes associated with common second-line targeted therapies given after first-line sunitinib to help inform decision making in this setting. The sample comprised patients with metastatic renal cell carcinoma (n = 257) who were receiving second-line everolimus, sorafenib, or temsirolimus. The results appeared to suggest that the risk of second-line treatment failure after first-line sunitinib was significantly higher with temsirolimus and sorafenib compared with everolimus. %26lt;br%26gt;This study was conducted to evaluate the treatment outcomes associated with common second-line targeted therapies given after first-line sunitinib for metastatic renal cell carcinoma (mRCC). The sample comprised patients with mRCC (n = 257) who were receiving second-line everolimus, sorafenib, or temsirolimus between April 1, 2008, and February 29, 2011, after first-line sunitinib treatment. The patients were followed-up from the start of second-line treatment until treatment failure (defined as advancement to a third-line therapy or to mortality) or the last observation in the medical and pharmacy databases. Treatment failure was observed in 38.5% (n = 99) of cases: 20.2% of patients (n = 52) advanced a line of treatment; and 18.3% of patients (n = 47) died. Kaplan-Meier analysis indicated a statistical difference in time to treatment failure among the 3 second-line targeted therapies (log-rank test, P = .045). The estimated 1-year cumulative probabilities of treatment failure were 49.9% for everolimus, 68.4% for sorafenib, and 71.4% for temsirolimus. In a multivariate Cox proportional hazards model, a higher adjusted risk of treatment failure vs. everolimus was observed for both temsirolimus (hazard ratio [HR] 2.05 [95% CI, 1.26-3.35]; P = .004) and sorafenib (HR 1.77 [95% CI, 1.02-3.07]; P = .043). The results of this real-world data analysis suggest that the risk of second-line treatment failure after first-line sunitinib was significantly higher with temsirolimus and sorafenib compared with everolimus.

• 出版日期2012-12